hotspot -WSS

hotspot

author：focus 2025-09-30 23:19:21 - browse：6

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Congress may force more Covid

WSS

Medicare Advantage enrollment hits roughly 33.4 million

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Why Congress must ban federal programs from using QALYs

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Medicare Advantage enrollment grows 7.1% to 33.4 million people

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

leisure time

hotspot

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Bright Health sells Medicare Advantage business to Molina

I learned firsthand about improving diversity in clinical trials

The high cost of giving birth even with insurance

Abridge raises $150m as clinical notes automation market heats up

Hollywood unions extend contract negotiations for actors

Surprise medical billing ban raises prices elsewhere

Apple is now the first public company to be valued at $3 trillion

EF3 tornado rips through North Carolina amid extreme weather nationwide

hotspot

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Hospitals are piloting generative AI tools as regulators play catch

In 'major milestone,' FDA approves first cell therapy for solid tumors

Tesla recalling nearly 16,000 of its 2021

Study identifies new proteins linked to dementia risk 25 years later

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

explore

knowledge

entertainment

focus